CPIC 2026 | Protheragen Session: Global Biomedical Cross-Border Transactions
Jun 25,2026
The global biopharmaceutical industry is undergoing a deep adjustment, with cross-border transactions shifting from "opportunity driven" to "strategic driven". How can Chinese innovative pharmaceutical companies find their positioning in the global landscape? How to accurately link high-quality overseas assets with the demand of the Chinese market? To this end, Protheragen and Tong Xieyi jointly organized the "Global Cross border Biopharmaceutical Transactions", focusing on core issues such as license in/out, cross-border mergers and acquisitions, and joint development, gathering frontline international transaction operators to share practical experience and cutting-edge insights. The conference aims to provide a practical and efficient communication platform for participants, promote multi-party exchanges and deep cooperation, and jointly explore sustainable and high-quality ways of global expansion.
Scan the code to register immediately
Early bird tickets are available for a limited time at a 25% discount!!
Special Session Schedule
Co-hosted: Protheragen
Opening & Welcome Remarks
Protheragen
TBD
Sean He：Novo Holdings A/S Partner and Head of China
Biopharma Innovation and Globalization - Challenges and Strategies
Pauline Lau：Suntec Medical, Inc. CEO
Partnering trends and opportunities in Europe
Jose-Maria Fernandez：Asabys Partners、AltamarCAM Partners
How Investors and Strategic Partners Assess Biopharma Assets: Lessons for Cross-Border Positioning and Readiness
Meghal Mistry：Zydus Lifesciences Limited Deputy General Manager of Business and Strategy
TBD
Natasha Qin：Sun Pharmaceutical Industries Limited Senior Director BD
Accessing emerging markets in Asia and Africa: marketneeds, partnership models, and experiences from reach52
Edward Booty：Reach52 Pte. Ltd CEO
Panel Discussion：From Interest to Execution: How Cross-Border BiopharmaCollaboration Works Today
Babar Khan：NEOM Investment Fund
Jasmine Wang：General Manager of Astellas (Beijing) Pharmaceutical R&D Co.,Ltd., Head of China Development
Ester Caffarel-Salvador：Chiesi Global Rare Diseases Director Strategic Innovation Global Rare Disease
Jason Peng：Santen Head of China Business Development, GBD
Calvin Chen：Novo Nordisk Associate Director Global Search & Evaluation
Follow or Contact Us
Follow the TONACEA Official WeChat Account and scan the QR code to register. Stay updated with the latest conference news.
Public Account QR Code
Registration QR Code
Conference Service Hotline
© 2026 TONACEA (Shanghai) Technology Development Co., Ltd. All rights reserved. All rights reserved.
